Evofem Biosciences, Inc. (EVFM) Stock

About Evofem Biosciences, Inc.

Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.

Evofem Biosciences, Inc. is headquartered in US.

Evofem Biosciences, Inc. (EVFM) stock trades at $0.01 with a market capitalization of $1.06M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.16, reflecting a net loss over the last twelve months, a negative price-to-book of -0.01, reflecting negative shareholders' equity, price-to-sales of 0.05. Over the past 52 weeks the stock has ranged between $0.00 and $0.02, and currently trades 50.0% below its 52-week high.

On profitability, Evofem Biosciences, Inc. generates a return on equity (ROE) of 8.58% (not meaningful, as shareholders' equity is negative), return on capital employed of 4.85%, an operating margin of -17.08%, a net profit margin of -29.90%.

Official website: www.evofem.com